Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, …
Apr 17, 2025 · Anonymous board for Novartis.
Novartis | Cafepharma
Nov 25, 2025 · Novartis (NVS) has received FDA approval for Itvisma, a groundbreaking gene therapy for spinal muscular atrophy (SMA). Itvisma is the first therapy targeting the genetic basis of SMA with …
Xolair | Cafepharma
Mar 4, 2025 · Xolair, a 20-year-old asthma drug sold by Roche (ROG.S) and Novartis (NOVN.S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage …
Medical Equipment/Device Sales - Cafepharma
Anonymous discussion boards for medical equipment/device companies
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales
ociperlimab | Cafepharma
In January, Novartis licensed the China-based company’s checkpoint inhibitor, tislelizumab. This morning, the Swiss pharma giant announced it has licensed ociperlimab, a late-stage TIGIT inhibitor, …
October 27 2025 - Novartis shares slip, Avidity soars after $12 billion ...
Oct 27, 2025 · Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly …
CMO | Cafepharma
Jul 25, 2025 · Ribon Therapeutics has named Sudha Parasuraman as its CMO. Parasuraman, last seen occupying the same role at X4 Pharmaceuticals, joins Ribon as it works to use money from the VC …
Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends.
‘Not prudent’ for Novartis to join GLP-1 obesity race as late-runner ...
Jul 18, 2024 · The breakout success of GLP-1 drugs by Novo Nordisk and Eli Lilly has persuaded many of their Big Pharma peers to enter their own newly acquired candidates into the obesity race. But …